Skip to main content

Free Content Tuberculosis research update

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

Summary Tuberculosis (TB) remains a major challenge to global public health in the 21st century. In 2007, there were an estimated 9.27 million new cases and 1.3 million deaths among HIV-negative patients with TB. The HIV-associated TB epidemic, drug-resistant disease, the need for better diagnostic assays and the limited efficacy of Bacille Calmette–Guerin vaccination are four important obstacles to further progress in global TB control. In this brief review, we provide a focused update on these four key areas of TB research.

French
La tuberculose (TB) reste un défi majeur mondial pour la santé publique au XXIe siècle. En 2007, il y avait 9,27 millions de nouveaux cas et 1,3 million de décès estimés parmi les cas de TB négatifs pour le VIH. L’épidémie de TB associée au VIH, la résistance de la maladie aux médicaments, la nécessité de meilleurs tests de diagnostic et l’efficacité limitée du Bacille Calmette Guérin (BCG) sont quatre obstacles importants à des progrès supplémentaires dans la lutte mondiale contre la TB. Dans cette revue nous fournissons une mise à jour focalisée sur ces quatre domaines clés de la recherche sur la TB.

Keywords: HIV; VIH; diagnosis; diagnostic; diagnóstico; drug resistance; resistencia a medicamentos; résistance aux médicaments; tuberculose; tuberculosis; vaccin; vaccine; vacuna

Document Type: Research Article

DOI: https://doi.org/10.1111/j.1365-3156.2010.02568.x

Affiliations:  South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town, South Africa

Publication date: 2010-08-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more